RT Journal Article
SR Electronic
T1 Prevalence of Erectile Dysfunction in Male Cancer: a Systematic Review and Meta-Analysis of Cross-Sectional Studies
JF British Journal of General Practice
JO Br J Gen Pract
FD British Journal of General Practice
SP bjgp20X714197
DO 10.3399/bjgp20X714197
A1 Damiano Pizzol
A1 Tao Xiao
A1 Smith Lee
A1 Guillermo Felipe López Sánchez
A1 Andrea Garolla
A1 Christopher Parris
A1 Yvonne Barnett
A1 Petre Cristian Ilie
A1 Pinar Soysal
A1 Jae Il Shin
A1 Mark A Tully
A1 Lin Yang
A1 Nicola Veronese
A1 Igor Grabovac
YR 2020
UL http://bjgp.org/content/early/2020/12/09/bjgp20X714197.abstract
AB Abstract Background: Sexual function is a fundamental aspect of health, well being and quality of life. In oncological male patients sexuality and erectile dysfunction (ED) can be compromise by psychological, pharmacological or physical components. Aim: We conducted a meta-analysis to estimate the prevalence of ED in all types of cancer and identify characteristics associated with ED in cancer survivors. Design and Setting: Systematic review and meta-analysis of cross-sectional studies. Method: Random effects models were used to pool the prevalence of ED as absolute estimates at three different stages (i.e., healthy, at diagnosis, and after treatment stages). A univariate meta-analysis (MA) regression including the three-level group variable as the only independent variable was used to assess the difference of prevalence of ED across the three groups. Further MA were conducted for studies involving patients at diagnosis and after treatment. Graphical comparisons of the prevalence of ED across these two stages of cancer treatment were given by a classic forest plot. Results: We included 43 studies with a total of 19,329 participants. Overall the pooled data of the included studies showed an ED prevalence of 40.72% (95%CI: 31.80-50.29) in cancer patients, with prevalence of 28.60% (95%CI: 12.10%-53.83%) at time of diagnosis and 42.70% (95%CI: 32.97%-53.03%) after treatment, across cancer locations. Conclusion: ED is particularly high in oncologic patients and may be influenced by neurovascular damage associated with treatment, hormonal therapy systemic chemo- or radiation therapy, as well as by psychological factors such as depression, anxiety, low self-esteem or issues with body image.